Product Code: PHA1245
The global Biopharmaceuticals Contract Manufacturing market is projected to grow at a CAGR of 10% by 2033.
“The Biopharmaceuticals Contract Manufacturing Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Every year, new and unique drug products and technologies come out. This changes the way biopharma works and what kinds of treatments are possible. This is partly because outsourcing gives them the ability and freedom to do so. Emerging and virtual companies that are driving the future pipeline depend heavily on external development partners, and not just for hard-to-make products. Even more well-known companies are signing contracts with CDMOs to get access to their resources and certain skills. In cell and gene therapy (CGT), many of the chemistry, manufacturing, and control (CMC) jobs, such as process development, analytical development, testing, manufacturing, and filling and finishing, are done by outside companies. Outsourcing can happen at almost any point in the life cycle of a treatment, all the way up until it goes on the market.
CGTs have problems that require expensive and hard-to-find consumables, tools, space, and talent. This could lead a company to think about outsourcing clinical through commercial manufacturing processes. Big companies have the means to develop and make products, but they may need help with certain tasks, such as specialised analytical assays or studies to improve the way a process works. Small companies, which make up most of the advanced biotherapeutic developers right now, don't have a lot of internal development and manufacturing capacity or experience, so they tend to outsource process development, process scaling up, and manufacturing.
What Questions Should You Ask before Buying a Market Research Report?
- How is the biopharmaceuticals contract manufacturing market evolving?
- What is driving and restraining the biopharmaceuticals contract manufacturing market?
- How will each biopharmaceuticals contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each biopharmaceuticals contract manufacturing submarket develop from 2023 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading biopharmaceuticals contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the biopharmaceuticals contract manufacturing projects for these leading companies?
- How will the industry evolve during the period between 2023 and 2033? What are the implications of biopharmaceuticals contract manufacturing projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the biopharmaceuticals contract manufacturing market?
- Where is the biopharmaceuticals contract manufacturing market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the biopharmaceuticals contract manufacturing market today, and over the next 10 years:
- Our 358-page report provides 140 tables and 167 charts/graphs exclusively to you
- The report highlights key lucrative areas in the industry so you can target them - NOW
- It contains in-depth analysis of global, regional and national sales and growth
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the biopharmaceuticals contract manufacturing market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
- You will find original analyses, with business outlooks and developments
- Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report:
Source
Service
- Process Development
- Fill & Finish Operations
- Analytical & QC Studies
- Packaging
Product
Company Size
Scale of Operations
- Preclinical
- Clinical
- Commercial
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 23 leading national markets:
North America
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- South-East Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
The report also includes profiles and for some of the leading companies in the Biopharmaceuticals Contract Manufacturing Market, 2023 to 2033, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth:
- AbbVie, Inc
- AGC Biologics
- Avantor, Inc
- Binex Co., Ltd
- Boehringer Ingelheim GmbH
- Cambrex Corporation
- Catalent Inc
- Curia Global, Inc
- Cytiva
- FUJIFILM Diosynth Biotechnologies
- JRS PHARMA
|
- Jubilant Pharma Limited
- KBI Biopharma
- Lonza
- Pfizer CentreOne
- ProBioGen
- Rentschler Biopharma SE
- Samsung Biologics
- Sandoz
- TOYOBO CO., LTD
- Thermo Fisher Scientific
- WuXi Biologics
|
Overall world revenue for Biopharmaceuticals Contract Manufacturing Market, 2023 to 2033 in terms of value the market will surpass US$15,280.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Biopharmaceuticals Contract Manufacturing Market, 2023 to 2033 report help you?
In summary, our 350+ page report provides you with the following knowledge:
- Revenue forecasts to 2033 for Biopharmaceuticals Contract Manufacturing Market, 2023 to 2033 Market, with forecasts for Source, service, product, company size, and scale of operations, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2033 for five regional and 23 key national markets - See forecasts for the Biopharmaceuticals Contract Manufacturing Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 22 of the major companies involved in the Biopharmaceuticals Contract Manufacturing Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Biopharmaceuticals Contract Manufacturing Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Biopharmaceuticals Contract Manufacturing Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report Include:
- 1.6 Who is This Report For?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Reports
- 1.10 About
2 Executive Summary
- 2.1 Emerging Outsourcing Trends in Biopharmaceuticals
- 2.2 Demand for RNA-based COVID-19 Vaccines Creates Revenue Opportunities for Contact Manufacturers
- 2.3 Increase in Investment in Research & Development
- 2.4 Analyst Viewpoint
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Rise in Investment by CMOs for Capacity Expansion
- 3.2.1.2 Cost and Time Saving Benefits Offered by Contract Services
- 3.2.1.3 Outsourcing as a Driver for Market Growth
- 3.2.1.4 Growing Investments in Orphan Drugs
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Pricing Pressure to Impede Market Growth
- 3.2.2.2 Regulatory Scenarios
- 3.2.2.3 Overcapacity Likely to Challenge Market Growth
- 3.2.3 Market Opportunities
- 3.2.3.1 Expansion of Fill and Finish CMOs
- 3.2.3.2 Emergence of Single-Use Bioprocessing Equipment & Solutions
- 3.2.3.3 Emerging Economies to Offer Lucrative Growth Opportunities
- 3.3 COVID-19 Impact Analysis
- 3.4 SWOT Analysis
- 3.4.1 Strengths
- 3.4.2 Weaknesses
- 3.4.3 Opportunities
- 3.4.4 Threats
- 3.5 Porter's Five Forces Analysis
- 3.5.1 Buyer Power
- 3.5.2 Supplier Power
- 3.5.3 Competitive Rivalry
- 3.5.4 Threat of Substitute
- 3.5.5 Threat of New Entrants
- 3.6 PEST Analysis
- 3.6.1 Political Factors Impacting Biopharmaceuticals Contract Manufacturing Market
- 3.6.2 Economic Factors Impacting Biopharmaceuticals Contract Manufacturing Market
- 3.6.3 Social Factors Impacting Biopharmaceuticals Contract Manufacturing Market
- 3.6.4 Technological Factors Impacting Biopharmaceuticals Contract Manufacturing Market
4 Biopharmaceuticals Contract Manufacturing Market Analysis by Source
- 4.1 Key Findings
- 4.2 Source Segment: Market Attractiveness Index
- 4.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Source
- 4.4 Mammalian
- 4.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 4.4.2 Market Share by Region, 2023 & 2033 (%)
- 4.5 Non-mammalian
- 4.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 4.5.2 Market Share by Region, 2023 & 2033 (%)
5 Biopharmaceuticals Contract Manufacturing Market Analysis by Service
- 5.1 Key Findings
- 5.2 Service Segment: Market Attractiveness Index
- 5.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Service
- 5.4 Process Development
- 5.4.1 Upstream Process Development
- 5.4.2 Downstream Process Development
- 5.4.3 Market Forecast by Region, 2023-2033 (US$ Mn)
- 5.4.4 Market Share by Region, 2023 & 2033 (%)
- 5.4.4.1 Market Forecast by Type, 2023-2033 (US$ Mn)
- 5.5 Fill & Finish Operations
- 5.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 5.5.2 Market Share by Region, 2023 & 2033 (%)
- 5.6 Analytical & QC Studies
- 5.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 5.6.2 Market Share by Region, 2023 & 2033 (%)
- 5.7 Packaging
- 5.7.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 5.7.2 Market Share by Region, 2023 & 2033 (%)
6 Biopharmaceuticals Contract Manufacturing Market Analysis by Product
- 6.1 Key Findings
- 6.2 Product Segment: Market Attractiveness Index
- 6.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Product
- 6.4 Biologics
- 6.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 6.4.2 Market Share by Region, 2023 & 2033 (%)
- 6.4.2.1 Market Forecast by Type, 2023-2033 (US$ Mn)
- 6.5 Biosimilars
- 6.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 6.5.2 Market Share by Region, 2023 & 2033 (%)
7 Biopharmaceuticals Contract Manufacturing Market Analysis by Scale of Operation
- 7.1 Key Findings
- 7.2 Scale of Operation Segment: Market Attractiveness Index
- 7.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
- 7.4 Preclinical
- 7.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 7.4.2 Market Share by Region, 2023 & 2033 (%)
- 7.5 Clinical
- 7.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 7.5.2 Market Share by Region, 2023 & 2033 (%)
- 7.6 Commercial
- 7.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 7.6.2 Market Share by Region, 2023 & 2033 (%)
8 Biopharmaceuticals Contract Manufacturing Market Analysis by Company Size
- 8.1 Key Findings
- 8.2 Company Size Segment: Market Attractiveness Index
- 8.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Company Size
- 8.4 Small
- 8.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 8.4.2 Market Share by Region, 2023 & 2033 (%)
- 8.5 Mid-sized
- 8.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 8.5.2 Market Share by Region, 2023 & 2033 (%)
- 8.6 Large
- 8.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
- 8.6.2 Market Share by Region, 2023 & 2033 (%)
9 Biopharmaceuticals Contract Manufacturing Market Analysis by Region
- 9.1 Key Findings
- 9.2 Regional Market Size Estimation and Forecast
10 North America Biopharmaceuticals Contract Manufacturing Market Analysis
- 10.1 Key Findings
- 10.2 North America Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
- 10.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
- 10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
- 10.5 Market Size Estimation and Forecast by Source, 2023-2033 (US$ Mn)
- 10.6 Market Size Estimation and Forecast by Service, 2023-2033 (US$ Mn)
- 10.7 Market Size Estimation and Forecast by Product, 2023-2033 (US$ Mn)
- 10.8 Market Size Estimation and Forecast by Scale of Operation, 2023-2033 (US$ Mn)
- 10.9 Market Size Estimation and Forecast by Company Size, 2023-2033 (US$ Mn)
- 10.10 U.S. Biopharmaceuticals Contract Manufacturing Market Analysis
- 10.11 Canada Biopharmaceuticals Contract Manufacturing Market Analysis
11 Europe Biopharmaceuticals Contract Manufacturing Market Analysis
- 11.1 Key Findings
- 11.2 Europe Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
- 11.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
- 11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
- 11.5 Market Size Estimation and Forecast by Source, 2023-2033 (US$ Mn)
- 11.6 Market Size Estimation and Forecast by Service, 2023-2033 (US$ Mn)
- 11.7 Market Size Estimation and Forecast by Product, 2023-2033 (US$ Mn)
- 11.8 Market Size Estimation and Forecast by Scale of Operation, 2023-2033 (US$ Mn)
- 11.9 Market Size Estimation and Forecast by Company Size, 2023-2033 (US$ Mn)
- 11.10 Germany Biopharmaceuticals Contract Manufacturing Market Analysis
- 11.11 UK Biopharmaceuticals Contract Manufacturing Market Analysis
- 11.12 France Biopharmaceuticals Contract Manufacturing Market Analysis
- 11.13 Italy Biopharmaceuticals Contract Manufacturing Market Analysis
- 11.13.1 Role of CDMO Business Across Italy
- 11.13.2 Investment by Major Players to Fuel Market Expansion
- 11.14 Spain Biopharmaceuticals Contract Manufacturing Market Analysis
- 11.15 Russia Biopharmaceuticals Contract Manufacturing Market Analysis
- 11.16 Rest of Europe Biopharmaceuticals Contract Manufacturing Market Analysis
12 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Analysis
- 12.1 Key Findings
- 12.2 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
- 12.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
- 12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
- 12.5 Market Size Estimation and Forecast by Source, 2023-2033 (US$ Mn)
- 12.6 Market Size Estimation and Forecast by Service, 2023-2033 (US$ Mn)
- 12.7 Market Size Estimation and Forecast by Product, 2023-2033 (US$ Mn)
- 12.8 Market Size Estimation and Forecast by Scale of Operation, 2023-2033 (US$ Mn)
- 12.9 Market Size Estimation and Forecast by Company Size, 2023-2033 (US$ Mn)
- 12.10 Japan Biopharmaceuticals Contract Manufacturing Market Analysis
- 12.11 China Biopharmaceuticals Contract Manufacturing Market Analysis
- 12.12 India Biopharmaceuticals Contract Manufacturing Market Analysis
- 12.12.1 The COVID-19 pandemic has brought India's biotechnology industry, especially biopharmaceuticals into the limelight
- 12.12.2 Piramal Pharma Ltd. Invests Minority Stake in CDMO Yapan Bio
- 12.12.3 Stelis Biopharma Limited Receives EU-GMP for Two of its Manufacturing Facilities
- 12.13 Australia Biopharmaceuticals Contract Manufacturing Market Analysis
- 12.14 South-East Asia Biopharmaceuticals Contract Manufacturing Market Analysis
- 12.15 Rest of Asia Pacific Biopharmaceuticals Contract Manufacturing Market Analysis
13 Latin America Biopharmaceuticals Contract Manufacturing Market Analysis
- 13.1 Key Findings
- 13.2 Latin America Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
- 13.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
- 13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
- 13.5 Market Size Estimation and Forecast by Source, 2023-2033 (US$ Mn)
- 13.6 Market Size Estimation and Forecast by Service, 2023-2033 (US$ Mn)
- 13.7 Market Size Estimation and Forecast by Product, 2023-2033 (US$ Mn)
- 13.8 Market Size Estimation and Forecast by Scale of Operation, 2023-2033 (US$ Mn)
- 13.9 Market Size Estimation and Forecast by Company Size, 2023-2033 (US$ Mn)
- 13.10 Brazil Biopharmaceuticals Contract Manufacturing Market Analysis
- 13.11 Mexico Biopharmaceuticals Contract Manufacturing Market Analysis
- 13.12 Argentina Biopharmaceuticals Contract Manufacturing Market Analysis
- 13.13 Colombia Biopharmaceuticals Contract Manufacturing Market Analysis
- 13.14 Rest of Latin America Biopharmaceuticals Contract Manufacturing Market Analysis
14 MEA Biopharmaceuticals Contract Manufacturing Market Analysis
- 14.1 Key Findings
- 14.2 MEA Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
- 14.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
- 14.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
- 14.5 Market Size Estimation and Forecast by Source, 2023-2033 (US$ Mn)
- 14.6 Market Size Estimation and Forecast by Service, 2023-2033 (US$ Mn)
- 14.7 Market Size Estimation and Forecast by Product, 2023-2033 (US$ Mn)
- 14.8 Market Size Estimation and Forecast by Scale of Operation, 2023-2033 (US$ Mn)
- 14.9 Market Size Estimation and Forecast by Company Size, 2023-2033 (US$ Mn)
- 14.10 GCC Biopharmaceuticals Contract Manufacturing Market Analysis
- 14.11 South Africa Biopharmaceuticals Contract Manufacturing Market Analysis
- 14.12 Rest of MEA Biopharmaceuticals Contract Manufacturing Market Analysis
15 Company Profiles
- 15.1 AbbVie, Inc.
- 15.1.1 Company Snapshot
- 15.1.2 Company Overview
- 15.1.3 Financial Analysis
- 15.1.3.1 Net Revenue, 2015-2022
- 15.1.3.2 R&D Expenses, 2015-2022
- 15.1.3.3 Regional Market Shares, 2022
- 15.1.4 Service Benchmarking
- 15.1.5 Strategic Outlook
- 15.2 AGC Biologics
- 15.2.1 Company Snapshot
- 15.2.2 Company Overview
- 15.2.3 Service Benchmarking
- 15.2.4 Strategic Outlook
- 15.3 Avantor, Inc.
- 15.3.1 Company Snapshot
- 15.3.2 Company Overview
- 15.3.3 Financial Analysis
- 15.3.3.1 Net Revenue, 2017-2022
- 15.3.3.2 Regional Market Shares, 2021
- 15.3.4 Service Benchmarking
- 15.3.5 Strategic Outlook
- 15.4 Binex Co., Ltd.
- 15.4.1 Company Snapshot
- 15.4.2 Company Overview
- 15.4.3 Service Benchmarking
- 15.5 Boehringer Ingelheim GmbH
- 15.5.1 Company Snapshot
- 15.5.2 Company Overview
- 15.5.3 Financial Analysis
- 15.5.3.1 Net Revenue, 2015-2021
- 15.5.4 Service Benchmarking
- 15.5.5 Strategic Outlook
- 15.6 FUJIFILM Diosynth Biotechnologies
- 15.6.1 Company Snapshot
- 15.6.2 Company Overview
- 15.6.3 Service Benchmarking
- 15.6.4 Strategic Outlook
- 15.7 Lonza
- 15.7.1 Company Snapshot
- 15.7.2 Company Overview
- 15.7.3 Financial Analysis
- 15.7.3.1 Net Revenue, 2015-2022
- 15.7.3.2 R&D Expenses, 2017-2021
- 15.7.4 Service Benchmarking
- 15.7.5 Strategic Outlook
- 15.8 ProBioGen
- 15.8.1 Company Snapshot
- 15.8.2 Company Overview
- 15.8.3 Service Benchmarking
- 15.8.4 Strategic Outlook
- 15.9 Rentschler Biopharma SE
- 15.9.1 Company Snapshot
- 15.9.2 Company Overview
- 15.9.3 Service Benchmarking
- 15.9.4 Strategic Outlook
- 15.10 Samsung Biologics
- 15.10.1 Company Snapshot
- 15.10.2 Company Overview
- 15.10.3 Service Benchmarking
- 15.10.4 Strategic Outlook
- 15.11 Sandoz
- 15.11.1 Company Snapshot
- 15.11.2 Company Overview
- 15.11.3 Financial Analysis
- 15.11.3.1 Net Revenue, 2015-2022
- 15.11.3.2 Regional Market Shares, 2021
- 15.11.4 Service Benchmarking
- 15.11.5 Strategic Outlook
- 15.12 TOYOBO CO., LTD.
- 15.12.1 Company Snapshot
- 15.12.2 Company Overview
- 15.12.3 Service Benchmarking
- 15.13 WuXi Biologics
- 15.13.1 Company Snapshot
- 15.13.2 Company Overview
- 15.13.3 Financial Analysis
- 15.13.3.1 Net Revenue, 2015-2022
- 15.13.3.2 Regional Market Shares, 2022
- 15.13.4 Service Benchmarking
- 15.13.5 Strategic Outlook
- 15.14 JRS PHARMA
- 15.14.1 Company Snapshot
- 15.14.2 Company Overview
- 15.14.3 Service Benchmarking
- 15.14.4 Strategic Outlook
- 15.15 Thermo Fisher Scientific
- 15.15.1 Company Snapshot
- 15.15.2 Company Overview
- 15.15.3 Financial Analysis
- 15.15.3.1 Net Revenue, 2015-2022
- 15.15.3.2 R&D, 2015-2022
- 15.15.3.3 Regional Market Shares, 2022
- 15.15.4 Service Benchmarking
- 15.16 Cambrex Corporation
- 15.16.1 Company Snapshot
- 15.16.2 Company Overview
- 15.16.3 Service Benchmarking
- 15.16.4 Strategic Outlook
- 15.17 Curia Global, Inc.
- 15.17.1 Company Snapshot
- 15.17.2 Company Overview
- 15.17.3 Service Benchmarking
- 15.17.4 Strategic Outlook
- 15.18 Pfizer CentreOne
- 15.18.1 Company Snapshot
- 15.18.2 Company Overview
- 15.18.3 Financial Analysis
- 15.18.3.1 Net Revenue, 2015-2022
- 15.18.3.2 R&D, 2015-2022
- 15.18.3.3 Regional Market Shares, 2022
- 15.18.4 Service Benchmarking
- 15.19 Jubilant Pharma Limited
- 15.19.1 Company Snapshot
- 15.19.2 Company Overview
- 15.19.3 Service Benchmarking
- 15.20 Catalent, Inc
- 15.20.1 Company Snapshot
- 15.20.2 Company Overview
- 15.20.3 Financial Analysis
- 15.20.3.1 Net Revenue, 2015-2022
- 15.20.4 Service Benchmarking
- 15.20.5 Strategic Outlook
- 15.21 KBI Biopharma
- 15.21.1 Company Snapshot
- 15.21.2 Company Overview
- 15.21.3 Service Benchmarking
- 15.21.4 Strategic Outlook
- 15.22 Cytiva
- 15.22.1 Company Snapshot
- 15.22.2 Company Overview
- 15.22.3 Service Benchmarking
- 15.22.4 Strategic Outlook
16 Conclusion and Recommendations
- 16.1 Concluding Remarks from
- 16.2 Recommendations for Market Players